BS: Chemical Engineering, Biomedical Engineering, Carnegie Mellon University
Gene and cell therapies have the potential to cure conditions ranging from rare genetic diseases to cancer. Viral vectors are the most common delivery vehicles for these therapies, with recombinant adeno-associated virus (rAAV) being selected most often for products in the development pipeline. However, rAAV manufacturing processes are not productive enough to meet clinical and commercial demands. To address this problem, we are developing a model rAAV production process to explore cell line engineering and process optimization strategies that will improve productivity and robustness.